EGFR and non-small cell lung carcinoma: For example, epidermal growth factor receptor (EGFR) T790M mutation and MET amplification appear at low frequency prior to treatment (<1% of cells), but are detected at a greater frequency in NSCLC patients CTCs after tyrosine kinase inhibitor (TKI) therapy [145].